Patients living with Parkinson's disease have few treatment choices, but many learn to function and slow disease progression in part by following a physical fitness regimen and taking a medication that replaces dopamine in the brain. The Michael J. Fox Foundation for Parkinson's Research is working with the pharmaceutical industry to study biomarkers that help doctors track disease progression and may lead to new drug targets. "A roadblock in developing new drugs has been the inability to predict what will happen over time," said principal investigator Kenneth Marek, a neurologist at Yale University.
Published in Brief: